CellVoyant Named Innovation Incubator Winner at AI Drug Discovery & Development Summit 2025
CellVoyant was named the Innovation Incubator Winner for 2025 at the AI Drug Discovery & Development Summit (AIDDD Summit), during the Innovation Forum held in Boston.
The Innovation Incubator recognises early-stage companies applying advanced technologies to address key challenges in drug discovery, development, and bioprocess innovation. CellVoyant was selected from a group of shortlisted finalists and was presented with the award during the summit.
Innovation Incubator Selection
In 2025, four companies were selected as Innovation Incubator finalists to present during the Innovation Forum:
- CellVoyant
- Model Medicines
- CapyBio
- AnuBio
Finalists were evaluated by a judging panel including Sagar Jain, Uli Stilz (Aerska, Novo Nordisk), John Mayfield (Flagship Pioneering), and Michaela Tolman, Ph.D. (Pfizer), bringing extensive industry experience across leading pharmaceutical and biotechnology organisations.
Why CellVoyant Was Recognised
CellVoyant develops AI platforms that analyse label-free live-cell imaging data to infer cell state, quality attributes, and likely future outcomes. By enabling continuous, non-destructive measurement and earlier insight into cell behaviour, CellVoyant’s technology supports faster learning and more predictable optimisation in research and bioprocess development workflows.
The Innovation Incubator recognition reflects growing industry interest in predictive, data-driven approaches that reduce reliance on slow, costly assays and trial-and-error experimentation.
Teams interested in applying predictive, label-free cell analytics can try FateView™ or book a demo to explore how the platform fits into real research and process optimisation workflows.